Search

Michel Boiron 1925-2018

It is with great sadness that we announce the passing of Professor Michel Boiron last December 3. Boiron was the founding President (1992-1994) of the European Hematology Association (EHA).

Read more

The European Hematology Association (EHA) Announces a New Era of Partnership with Interplan as its New Core PCO

The European Hematology Association (EHA) is delighted to announce to the conference and meeting community the outcome of its Core PCO Invitation To Tender (ITT).

Read more

Congress Sponsor Program

Join us at the EHA Annual Congress, where you have the unique opportunity to connect and grow with a community of hematology experts.

Read more

VIRTUAL: EHA-TSH Hematology Tutorial

June 25&26, 2021

Meeting Chairs:

Prof S Eichinger (European Hematology Association)
Prof H Özsan (Turkish Society of Hematology)
In close collaboration with the Turkish Society of Hematology, EHA has annually organized  live, joint tutorials (nine in the series), which are organized as part of…

Read more

Revision of the EU’s pharmaceutical legislation

Background on the reformIn April 2023, the European Commission (EC) published two proposals to revise the existing (and outdated) pharmaceutical legislation. This includes legislation on medicines for children and rare diseases.

Read more

IMI2 Call for Research Proposals

The indicative budget for this topic is 40 million Euro, half of which by way of an in kind contribution from Industry Consortium EFPIA (European Federation of Pharmaceutical Industries and Associations) companies.

Read more

EHA-SHRC Hematology Tutorial on Thalassemia

Dates: May 10-11, 2018
Location: Shiraz, Iran
Chairs: M Karimi, MD Cappellini & A Taher

  

EHA in close collaboration with Shiraz Hematology Research Center and the Shiraz Medical Center, endorsed by the Iranian Pediatric Hematology Oncology Society, organize a two day tutorial on “Thalassemia”.…

Read more

Scientific relations

Engagement and collaboration with EU scientific and research policies, networks and projects on behalf of hematologists in a way that benefits all sides – researchers, diagnosticians and clinicians as well as policymakers and regulators – is an important part of…

Read more